Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Cash from Investing Activities (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Cash from Investing Activities for 12 consecutive years, with -$126000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 500.0% to -$126000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$188000.0, a 408.11% decrease, with the full-year FY2025 number at -$188000.0, down 408.11% from a year prior.
  • Cash from Investing Activities was -$126000.0 for Q4 2025 at Ekso Bionics Holdings, down from -$12000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $1000.0 in Q4 2021 to a low of -$5.0 million in Q4 2022.
  • A 5-year average of -$396857.1 and a median of -$30500.0 in 2024 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 503500.0% in 2022, then soared 99.15% in 2023.
  • Ekso Bionics Holdings' Cash from Investing Activities stood at $1000.0 in 2021, then tumbled by 503500.0% to -$5.0 million in 2022, then skyrocketed by 99.15% to -$43000.0 in 2023, then surged by 51.16% to -$21000.0 in 2024, then plummeted by 500.0% to -$126000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Cash from Investing Activities are -$126000.0 (Q4 2025), -$12000.0 (Q3 2025), and -$40000.0 (Q2 2025).